BioSpace News Archive

Cyclerion Therapeutics, Inc. will participate in a webinar hosted by the United Mitochondrial Disease Foundation (UMDF) on Tuesday, June 28th at 8 a.m. EDT with a live Q&A.

CytoDyn Inc. announced today that Tanya Urbach, Board Chair will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022.

Athenex, Inc., (NASDAQ: ATNX), today announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and funds managed by Oaktree Capital Management, L.P. (“Oaktree”) for $85 million.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in the MM cohort of COVALENT-101, the company’s Phase I clinical trial evaluating BMF-219, Biomea’s covalent menin inhibitor, in patients with R/R AML, ALL, DLBCL, and MM.

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 27th Annual European Society for Animal Cell Technology (ESCAT), being held from June 26 - 29, 2022 at the Lisbon Congress Centre in Lisbon, Portugal.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group’s panel discussion on Innovations in ALS: Exploring New Treatments In Development, which will take place on Tuesday, June 28th, 2022.

Global Life Sciences Industry Executive Transitions from Interim CEO Role to Full-Time Leadership Position to Lead Commercialization of Disruptive Diagnostic Technology.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx” or “Company”), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), is planning to expand its ophthalmic clinical development.

PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder.

Launch of Termeer Scholars Program Will Support Biomedical Researchers and Bring Emerging Talent into the Foundation’s Network of Biotech Innovators.